BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11085524)

  • 1. Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand LGD1069 (targretin).
    Agarwal VR; Bischoff ED; Hermann T; Lamph WW
    Cancer Res; 2000 Nov; 60(21):6033-8. PubMed ID: 11085524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.
    Bischoff ED; Gottardis MM; Moon TE; Heyman RA; Lamph WW
    Cancer Res; 1998 Feb; 58(3):479-84. PubMed ID: 9458093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand.
    Gottardis MM; Bischoff ED; Shirley MA; Wagoner MA; Lamph WW; Heyman RA
    Cancer Res; 1996 Dec; 56(24):5566-70. PubMed ID: 8971154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of LGD1069 (Targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyoma.
    Gamage SD; Bischoff ED; Burroughs KD; Lamph WW; Gottardis MM; Walker CL; Fuchs-Young R
    J Pharmacol Exp Ther; 2000 Nov; 295(2):677-81. PubMed ID: 11046105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines.
    Song JI; Lango MN; Hwang JD; Drenning SD; Zeng Q; Lamph WW; Grandis JR
    Cancer Res; 2001 Aug; 61(15):5919-25. PubMed ID: 11479234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice.
    Wu K; Zhang Y; Xu XC; Hill J; Celestino J; Kim HT; Mohsin SK; Hilsenbeck SG; Lamph WW; Bissonette R; Brown PH
    Cancer Res; 2002 Nov; 62(22):6376-80. PubMed ID: 12438218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor alpha and interleukin 11 secreted by malignant breast epithelial cells inhibit adipocyte differentiation by selectively down-regulating CCAAT/enhancer binding protein alpha and peroxisome proliferator-activated receptor gamma: mechanism of desmoplastic reaction.
    Meng L; Zhou J; Sasano H; Suzuki T; Zeitoun KM; Bulun SE
    Cancer Res; 2001 Mar; 61(5):2250-5. PubMed ID: 11280794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.
    Wu K; Kim HT; Rodriquez JL; Hilsenbeck SG; Mohsin SK; Xu XC; Lamph WW; Kuhn JG; Green JE; Brown PH
    Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):467-74. PubMed ID: 12010861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haploid inactivation of the amplified-in-breast cancer 3 coactivator reduces the inhibitory effect of peroxisome proliferator-activated receptor gamma and retinoid X receptor on cell proliferation and accelerates polyoma middle-T antigen-induced mammary tumorigenesis in mice.
    Zhang H; Kuang SQ; Liao L; Zhou S; Xu J
    Cancer Res; 2004 Oct; 64(19):7169-77. PubMed ID: 15466215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma.
    Yen WC; Prudente RY; Lamph WW
    Breast Cancer Res Treat; 2004 Nov; 88(2):141-8. PubMed ID: 15564797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The retinoid X receptor-selective ligand, LGD1069, inhibits tumor-induced angiogenesis via suppression of VEGF in human non-small cell lung cancer.
    Fu J; Ding Y; Huang D; Li H; Chen X
    Cancer Lett; 2007 Apr; 248(1):153-63. PubMed ID: 17027148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model.
    Cohen LA; Pittman B; Wang CX; Aliaga C; Yu L; Moyer JD
    Cancer Res; 2001 Dec; 61(24):8683-8. PubMed ID: 11751385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limited cooperation between peroxisome proliferator-activated receptors and retinoid X receptor agonists in sebocyte growth and development.
    Kim MJ; Deplewski D; Ciletti N; Michel S; Reichert U; Rosenfield RL
    Mol Genet Metab; 2001 Nov; 74(3):362-9. PubMed ID: 11708867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays.
    Kim HT; Kong G; Denardo D; Li Y; Uray I; Pal S; Mohsin S; Hilsenbeck SG; Bissonnette R; Lamph WW; Johnson K; Brown PH
    Cancer Res; 2006 Dec; 66(24):12009-18. PubMed ID: 17178900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure.
    Bischoff ED; Heyman RA; Lamph WW
    J Natl Cancer Inst; 1999 Dec; 91(24):2118. PubMed ID: 10601384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis.
    Lubet RA; Christov K; Nunez NP; Hursting SD; Steele VE; Juliana MM; Eto I; Grubbs CJ
    Carcinogenesis; 2005 Feb; 26(2):441-8. PubMed ID: 15591091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors.
    Cohen LA; Marks PA; Rifkind RA; Amin S; Desai D; Pittman B; Richon VM
    Anticancer Res; 2002; 22(3):1497-504. PubMed ID: 12168829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma.
    Klopper JP; Berenz A; Hays WR; Sharma V; Pugazhenthi U; Janssen J; Singh M; Bissonnette RP; Haugen BR
    Clin Cancer Res; 2008 Jan; 14(2):589-96. PubMed ID: 18223235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis.
    Yin Y; Russell RG; Dettin LE; Bai R; Wei ZL; Kozikowski AP; Kopelovich L; Glazer RI
    Cancer Res; 2005 May; 65(9):3950-7. PubMed ID: 15867396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention.
    Kong G; Kim HT; Wu K; DeNardo D; Hilsenbeck SG; Xu XC; Lamph WW; Bissonnette R; Dannenberg AJ; Brown PH
    Cancer Res; 2005 Apr; 65(8):3462-9. PubMed ID: 15833882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.